Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for O14681

Entry ID Method Resolution Chain Position Source
AF-O14681-F1 Predicted AlphaFoldDB

226 variants for O14681

Variant ID(s) Position Change Description Diseaes Association Provenance
rs1938981293
RCV001291079
248 P>S Intellectual disability [ClinVar] Yes ClinVar
dbSNP
rs1430252311
CA383184375
3 D>G No ClinGen
TOPMed
rs1210035779
CA383184438
6 K>N No ClinGen
gnomAD
rs1034665480
CA230478843
6 K>Q No ClinGen
TOPMed
rs757684668
CA6348407
8 F>I No ClinGen
ExAC
gnomAD
rs1028818107
CA230478852
9 L>F No ClinGen
TOPMed
gnomAD
TCGA novel 9 L>P Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs377285559
CA6348408
10 Q>R No ClinGen
ESP
ExAC
TOPMed
gnomAD
CA230478856
rs371166633
11 D>Y No ClinGen
ESP
CA383184500
rs1248055655
12 L>P No ClinGen
gnomAD
CA6348409
rs750911358
13 A>V No ClinGen
ExAC
TOPMed
gnomAD
rs1256404202
CA383184511
14 R>I No ClinGen
gnomAD
rs1253897850
CA383175482
16 I>V No ClinGen
gnomAD
rs1456760538
CA383175496
17 K>R No ClinGen
TOPMed
gnomAD
rs1423012400
CA383175508
18 D>G No ClinGen
gnomAD
rs754468044
CA6348442
19 S>A No ClinGen
ExAC
TOPMed
gnomAD
CA230448716
rs1033679626
19 S>F No ClinGen
Ensembl
CA230448725
rs959439900
22 G>D No ClinGen
Ensembl
CA383175561
rs1419853087
23 I>T No ClinGen
gnomAD
rs780869331
CA6348443
23 I>V No ClinGen
ExAC
rs750770393
CA6348444
25 T>A No ClinGen
ExAC
gnomAD
rs1388706495
CA383175589
26 I>N No ClinGen
gnomAD
rs758650270
CA230448790
26 I>V No ClinGen
gnomAD
CA383175623
rs1478795773
29 L>I No ClinGen
TOPMed
VAR_065459 30 D>G some patients with early onset breast cancer [UniProt] No UniProt
rs1266678551
CA383175652
31 A>V No ClinGen
TOPMed
rs1436886093
CA383175656
32 R>* No ClinGen
gnomAD
rs755888723
CA6348445
32 R>Q No ClinGen
ExAC
gnomAD
CA230448806
rs11538202
34 Q>R No ClinGen
Ensembl
rs1015595415
CA230448813
35 Q>E No ClinGen
TOPMed
CA383175687
rs1290620281
36 K>N No ClinGen
TOPMed
rs961210908
CA230448826
38 E>K No ClinGen
TOPMed
rs777575493
CA383175709
39 E>D No ClinGen
ExAC
gnomAD
rs143089007
CA6348447
41 R>C No ClinGen
1000Genomes
ESP
ExAC
TOPMed
gnomAD
CA6348448
rs559933286
41 R>H No ClinGen
1000Genomes
ExAC
TOPMed
gnomAD
CA383175725
rs1227885517
42 R>Q No ClinGen
gnomAD
CA6348449
rs576924332
44 R>K No ClinGen
1000Genomes
ExAC
gnomAD
rs747137168
CA6348451
46 S>G No ClinGen
ExAC
gnomAD
CA383175751
rs1342700092
46 S>N No ClinGen
TOPMed
rs1255568465
CA383175762
47 S>G No ClinGen
gnomAD
rs768825664
CA6348453
47 S>I No ClinGen
ExAC
CA6348455
rs762050242
48 V>A No ClinGen
ExAC
gnomAD
rs777026055
CA6348454
48 V>F No ClinGen
ExAC
gnomAD
CA383175813
rs1343340080
49 L>F No ClinGen
gnomAD
CA6348456
rs373668336
50 A>T No ClinGen
ESP
ExAC
TOPMed
gnomAD
rs1349997744
CA383175824
50 A>V No ClinGen
TOPMed
rs766788418
CA230448900
53 R>G No ClinGen
Ensembl
rs1324920326
CA383175856
53 R>K No ClinGen
TOPMed
CA230448903
rs1043914
54 A>P No ClinGen
Ensembl
rs868521544
CA230448918
55 Q>K No ClinGen
Ensembl
CA383175908
rs1401928711
57 I>T No ClinGen
gnomAD
rs763226051
CA6348458
58 E>Q No ClinGen
ExAC
TOPMed
gnomAD
rs1171209886
CA383175922
58 E>V No ClinGen
TOPMed
rs766964225
CA6348459
59 R>Q No ClinGen
ExAC
TOPMed
gnomAD
rs187402952
CA230448930
59 R>W No ClinGen
1000Genomes
TOPMed
gnomAD
rs1176987567
CA383175983
63 S>R No ClinGen
gnomAD
CA6348494
rs765076061
64 E>G No ClinGen
ExAC
gnomAD
CA6348495
rs368526220
66 R>C No ClinGen
ESP
ExAC
TOPMed
gnomAD
CA230449886
rs555329927
66 R>H Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
gnomAD
CA6348496
COSM1585479
rs758348980
70 R>I Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic] No ClinGen
cosmic curated
ExAC
NCI-TCGA
gnomAD
TCGA novel 71 I>V Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
TCGA novel 80 G>E Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA230449923
rs866858234
83 W>* No ClinGen
TOPMed
gnomAD
rs982649922
CA230450881
84 F>C No ClinGen
TOPMed
rs761501242
CA6348515
86 L>F No ClinGen
ExAC
TOPMed
gnomAD
CA383176727
rs1199505779
87 L>P No ClinGen
gnomAD
CA383176733
rs1486855832
CA383176734
88 L>F No ClinGen
TOPMed
gnomAD
CA383176732
rs781526161
88 L>S No ClinGen
TOPMed
rs781526161
CA230450931
88 L>W No ClinGen
TOPMed
rs1203708950
CA383176753
91 R>Q Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
TOPMed
gnomAD
rs1486713589
CA383176756
92 V>I No ClinGen
TOPMed
CA383176793
rs1184018568
97 L>P No ClinGen
TOPMed
gnomAD
CA383176808
rs1477844259
99 S>L Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
TOPMed
gnomAD
TCGA novel 100 V>A Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs541463043
CA383176809
100 V>I No ClinGen
1000Genomes
ExAC
gnomAD
CA6348521
rs541463043
100 V>L No ClinGen
1000Genomes
ExAC
gnomAD
TCGA novel 103 R>* Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA6348522
rs751419166
103 R>Q No ClinGen
ExAC
gnomAD
rs1262939623
CA383176842
105 I>T No ClinGen
TOPMed
CA6348524
rs777661044
106 G>S No ClinGen
ExAC
gnomAD
CA6348543
rs764238263
108 P>Q No ClinGen
ExAC
gnomAD
CA383177139
rs1164887003
108 P>S No ClinGen
TOPMed
rs1259071951
CA383177215
114 V>I No ClinGen
TOPMed
rs757313787
CA6348545
115 W>* No ClinGen
ExAC
gnomAD
rs757313787
CA230451486
115 W>C No ClinGen
ExAC
gnomAD
COSM3415645
rs534625909
CA6348546
116 S>L Variant assessed as Somatic; 0.0 impact. large_intestine [NCI-TCGA, Cosmic] No ClinGen
cosmic curated
1000Genomes
ExAC
NCI-TCGA
TOPMed
gnomAD
CA383177245
rs1184249657
116 S>P No ClinGen
TOPMed
CA6348549
rs1043918
119 E>G No ClinGen
ExAC
gnomAD
CA6348552
rs781717797
123 T>M No ClinGen
ExAC
TOPMed
gnomAD
rs1233875979
CA383177394
127 S>I No ClinGen
TOPMed
CA383177396
rs1395991873
127 S>R No ClinGen
gnomAD
CA383177409
rs1043919
129 L>F No ClinGen
TOPMed
CA230451541
rs1043919
129 L>V No ClinGen
TOPMed
CA383177445
rs1591358058
131 V>G No ClinGen
Ensembl
rs1591358064
CA383177450
COSM1585478
132 L>F endometrium [Cosmic] No ClinGen
cosmic curated
Ensembl
TCGA novel 133 P>L Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs1212896041
CA383177502
136 V>L No ClinGen
TOPMed
TCGA novel 140 V>L Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs1289704430
CA383177549
140 V>M No ClinGen
TOPMed
rs773025733
CA6348555
144 I>M No ClinGen
ExAC
gnomAD
rs1211520286
CA383177796
153 A>V No ClinGen
gnomAD
CA230452313
rs1017432096
155 E>K No ClinGen
TOPMed
gnomAD
CA230452319
rs964507866
156 V>I No ClinGen
TOPMed
gnomAD
CA383177812
rs964507866
156 V>L No ClinGen
TOPMed
gnomAD
rs777357915
CA6348573
158 G>R No ClinGen
ExAC
gnomAD
rs777357915
CA6348572
158 G>W No ClinGen
ExAC
gnomAD
TCGA novel 160 K>N Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA383177844
rs1408048016
161 P>S No ClinGen
gnomAD
TCGA novel 163 P>S Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs1415107267
CA383177875
165 P>L No ClinGen
TOPMed
rs199956275
CA6348576
167 V>I No ClinGen
ESP
ExAC
TOPMed
gnomAD
rs932804528
CA230452375
168 S>C No ClinGen
Ensembl
TCGA novel 169 K>N Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs771869037
CA6348577
171 I>T No ClinGen
ExAC
TOPMed
gnomAD
CA383177938
rs1213167263
174 M>I No ClinGen
TOPMed
CA383177935
rs1369207768
174 M>T No ClinGen
gnomAD
rs1051704625
CA230452382
175 L>I No ClinGen
Ensembl
CA6348579
rs760547660
176 F>L No ClinGen
ExAC
TOPMed
gnomAD
CA6348580
rs765307351
177 N>S No ClinGen
ExAC
gnomAD
TCGA novel 181 Q>* Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA383178017
rs1225662439
186 I>M No ClinGen
gnomAD
rs1234698331
CA383178016
186 I>T No ClinGen
gnomAD
CA6348597
rs746803273
191 V>A No ClinGen
ExAC
gnomAD
CA383178064
rs746803273
191 V>E No ClinGen
ExAC
gnomAD
CA383178076
rs1339805150
193 L>F No ClinGen
gnomAD
CA230453352
rs914768960
195 P>L No ClinGen
Ensembl
VAR_065460 195 P>W some patients with early onset breast cancer; requires 2 nucleotide substitutions [UniProt] No UniProt
VAR_065461 196 I>D some patients with early onset breast cancer; requires 2 nucleotide substitutions [UniProt] No UniProt
CA6348598
rs768642013
196 I>V No ClinGen
ExAC
gnomAD
CA383178103
rs1273559472
197 H>R No ClinGen
gnomAD
VAR_065462 197 H>Y some patients with early onset breast cancer [UniProt] No UniProt
VAR_065463 199 V>H some patients with early onset breast cancer; requires 2 nucleotide substitutions [UniProt] No UniProt
CA6348599
rs776530046
199 V>L No ClinGen
ExAC
gnomAD
rs963507559
CA230453384
200 G>D No ClinGen
TOPMed
rs373773329
CA6348602
200 G>R No ClinGen
ESP
ExAC
TOPMed
gnomAD
rs373773329
CA6348601
200 G>S No ClinGen
ESP
ExAC
TOPMed
gnomAD
rs759742348
CA6348603
203 V>I No ClinGen
ExAC
gnomAD
rs767996205
CA6348604
205 L>I No ClinGen
ExAC
TOPMed
gnomAD
CA383178150
rs1170259605
205 L>P No ClinGen
TOPMed
CA6348605
rs753175859
206 L>M No ClinGen
ExAC
gnomAD
rs1565331728
CA383178160
207 H>R No ClinGen
Ensembl
rs764744779
CA6348608
216 C>Y No ClinGen
ExAC
CA383178236
rs1431176371
218 E>A No ClinGen
TOPMed
CA6348610
rs756747810
220 R>C No ClinGen
ExAC
TOPMed
gnomAD
CA383178251
rs1565331774
220 R>H Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
Ensembl
NCI-TCGA
CA6348611
rs778428992
223 N>H No ClinGen
ExAC
gnomAD
TCGA novel 226 I>N Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA383178307
rs1187860758
226 I>T No ClinGen
gnomAD
CA383178322
rs1418744446
228 M>R No ClinGen
gnomAD
CA230454213
rs1051274719
231 R>Q Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
TOPMed
gnomAD
rs1157223457
CA383178344
231 R>W Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
gnomAD
CA230454250
rs944559335
235 I>V No ClinGen
Ensembl
TCGA novel 236 E>* Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs772477314
CA6348624
236 E>A No ClinGen
ExAC
gnomAD
CA230454253
rs3017282
236 E>K No ClinGen
Ensembl
CA6348625
rs775831062
237 R>G No ClinGen
ExAC
gnomAD
rs1052273727
CA230454264
237 R>K No ClinGen
TOPMed
CA6348626
rs761160071
237 R>S No ClinGen
ExAC
gnomAD
rs892392286
CA230454267
240 P>S No ClinGen
TOPMed
rs892392286
CA383178436
240 P>T No ClinGen
TOPMed
CA6348628
rs754323798
241 Y>F No ClinGen
ExAC
gnomAD
CA6348629
rs762315438
242 Y>C No ClinGen
ExAC
gnomAD
rs1277430275
CA383178597
253 T>I No ClinGen
gnomAD
CA383178612
rs1365125068
255 M>V No ClinGen
TOPMed
rs1591360728
CA383178643
257 S>T No ClinGen
Ensembl
TCGA novel 257 S>Y Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA230454340
rs372602233
259 Y>C No ClinGen
ESP
CA383179119
rs1249976689
262 S>R No ClinGen
gnomAD
rs775886056
CA6348650
264 C>W No ClinGen
ExAC
gnomAD
rs747178296
CA383179191
268 I>F No ClinGen
ExAC
gnomAD
rs747178296
CA6348651
268 I>L No ClinGen
ExAC
gnomAD
CA383179230
rs1452364929
271 P>S Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
NCI-TCGA
gnomAD
rs1201058323
CA383179258
272 L>F No ClinGen
TOPMed
CA6348652
rs768907071
276 S>N No ClinGen
ExAC
gnomAD
rs1166077392
CA383179370
279 E>D No ClinGen
gnomAD
rs548662841
CA230455433
279 E>G No ClinGen
1000Genomes
gnomAD
rs548662841
CA383179369
279 E>V No ClinGen
1000Genomes
gnomAD
CA383179375
rs1395164206
280 A>T No ClinGen
gnomAD
TCGA novel 281 K>N Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
CA383179426
rs1591361744
282 T>P No ClinGen
Ensembl
TCGA novel 284 G>D Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs972394188
CA230455439
286 A>T No ClinGen
Ensembl
CA6348655
rs762073143
286 A>V No ClinGen
ExAC
CA383179540
rs1555055033
287 Y>C No ClinGen
Ensembl
rs919957231
CA230456346
290 Q>H No ClinGen
TOPMed
rs758571587
CA6348667
290 Q>L No ClinGen
ExAC
gnomAD
rs371275461
CA6348668
292 R>C Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] No ClinGen
ESP
ExAC
NCI-TCGA
TOPMed
gnomAD
rs747081882
CA6348669
292 R>H No ClinGen
ExAC
TOPMed
gnomAD
rs768981828
CA383179740
293 L>F No ClinGen
ExAC
gnomAD
CA6348670
rs768981828
293 L>V No ClinGen
ExAC
gnomAD
CA6348671
rs776697971
297 V>A No ClinGen
ExAC
gnomAD
CA383179855
rs1327578743
299 F>S No ClinGen
gnomAD
rs748588966
CA6348672
301 S>N No ClinGen
ExAC
gnomAD
CA383179890
rs1291585663
302 N>S No ClinGen
gnomAD
CA383179896
rs1334237838
303 R>K No ClinGen
gnomAD
CA6348673
rs570993633
310 Y>D No ClinGen
1000Genomes
ExAC
gnomAD
CA6348674
rs570993633
310 Y>H No ClinGen
1000Genomes
ExAC
gnomAD
CA6348675
rs373537623
313 S>L No ClinGen
ExAC
TOPMed
gnomAD
CA230456410
rs746913266
314 A>V No ClinGen
TOPMed
CA383180045
rs1203112235
315 L>P No ClinGen
gnomAD
CA383180051
rs1260752303
316 S>N No ClinGen
gnomAD
CA383180067
rs1380867159
317 S>N No ClinGen
TOPMed
CA6348677
VAR_065464
rs375652371
319 T>A some patients with early onset breast cancer [UniProt] No ClinGen
UniProt
ESP
ExAC
TOPMed
dbSNP
gnomAD
rs759030816
CA6348678
319 T>I No ClinGen
ExAC
gnomAD
CA383180081
rs375652371
319 T>P No ClinGen
ESP
ExAC
TOPMed
gnomAD
CA6348679
rs368640507
321 A>V No ClinGen
ESP
ExAC
TOPMed
gnomAD
CA230456446
rs543422472
322 E>K No ClinGen
Ensembl
CA383180137
rs1381255890
324 F>L No ClinGen
TOPMed
CA6348680
rs752258627
325 P>L No ClinGen
ExAC
gnomAD
TCGA novel 325 P>L Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs1591362738
CA383180152
325 P>S No ClinGen
Ensembl
rs755968101
CA6348681
326 S>P No ClinGen
ExAC
gnomAD
CA6348682
rs763747205
327 P>L No ClinGen
ExAC
gnomAD
rs1451147333
CA383180168
327 P>S No ClinGen
TOPMed
gnomAD
CA383180187
rs1565334270
328 H>Q No ClinGen
Ensembl
rs757330810
CA6348684
328 H>Y No ClinGen
ExAC
TOPMed
gnomAD
rs371870792
CA6348685
329 P>L Variant assessed as Somatic; 4.66e-05 impact. [NCI-TCGA] No ClinGen
ESP
ExAC
NCI-TCGA
TOPMed
gnomAD
CA383180207
rs1295372984
330 S>L No ClinGen
TOPMed
gnomAD
rs1233934373
CA383180202
330 S>T No ClinGen
gnomAD
CA6348688
rs781510255
334 L>P No ClinGen
ExAC
gnomAD
rs748272966
CA6348689
336 A>T No ClinGen
ExAC
TOPMed
gnomAD
rs371540566
CA6348690
336 A>V No ClinGen
ESP
ExAC
TOPMed
gnomAD
TCGA novel 337 T>A Variant assessed as Somatic; impact. [NCI-TCGA] No NCI-TCGA
rs778049532
CA6348691
339 G>D No ClinGen
ExAC
TOPMed
gnomAD
rs568514385
CA6348692
340 H>D No ClinGen
1000Genomes
ExAC
gnomAD
CA6348693
rs771481834
341 H>G No ClinGen
ExAC
TOPMed

1 associated diseases with O14681

Without disease ID

No regional properties for O14681

Type Name Position InterPro Accession
No domain, repeats, and functional sites for O14681

Functions

Description
EC Number
Subcellular Localization
  • Nucleus membrane ; Multi-pass membrane protein
  • Cytoplasm
  • Endoplasmic reticulum membrane ; Multi-pass membrane protein
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

7 GO annotations of cellular component

Name Definition
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
endoplasmic reticulum The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).
endoplasmic reticulum membrane The lipid bilayer surrounding the endoplasmic reticulum.
Golgi apparatus A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways.
integral component of membrane The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
membrane A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
nuclear membrane Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space.

1 GO annotations of molecular function

Name Definition
importin-alpha family protein binding Binding to a member of the importin-alpha family.

3 GO annotations of biological process

Name Definition
apoptotic process A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
macroautophagy The major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane-bounded autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane-bounded structure. Autophagosomes then fuse with a lysosome (or vacuole) releasing single-membrane-bounded autophagic bodies that are then degraded within the lysosome (or vacuole). Some types of macroautophagy, e.g. pexophagy, mitophagy, involve selective targeting of the targets to be degraded.
negative regulation of cell growth Any process that stops, prevents, or reduces the frequency, rate, extent or direction of cell growth.

3 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q61070 Ei24 Etoposide-induced protein 2.4 Mus musculus (Mouse) PR
Q4KM77 Ei24 Etoposide-induced protein 2.4 homolog Rattus norvegicus (Rat) PR
Q20123 epg-4 Ectopic P granules protein 4 Caenorhabditis elegans PR
10 20 30 40 50 60
MADSVKTFLQ DLARGIKDSI WGICTISKLD ARIQQKREEQ RRRRASSVLA QRRAQSIERK
70 80 90 100 110 120
QESEPRIVSR IFQCCAWNGG VFWFSLLLFY RVFIPVLQSV TARIIGDPSL HGDVWSWLEF
130 140 150 160 170 180
FLTSIFSALW VLPLFVLSKV VNAIWFQDIA DLAFEVSGRK PHPFPSVSKI IADMLFNLLL
190 200 210 220 230 240
QALFLIQGMF VSLFPIHLVG QLVSLLHMSL LYSLYCFEYR WFNKGIEMHQ RLSNIERNWP
250 260 270 280 290 300
YYFGFGLPLA FLTAMQSSYI ISGCLFSILF PLFIISANEA KTPGKAYLFQ LRLFSLVVFL
310 320 330
SNRLFHKTVY LQSALSSSTS AEKFPSPHPS PAKLKATAGH